New research implicates natural toxin as triggering Parkinson's disease

Feb 10, 2011

In new research from Saint Louis University, investigators have found evidence that a toxin produced by the brain is responsible for the series of cellular events that lead to Parkinson's disease. The study, published in PLoS One, found that the brain toxin DOPAL plays a key role in killing the dopamine neurons which trigger the illness.

In earlier research, Saint Louis University investigators found that DOPAL seemed to be responsible for killing healthy dopamine cells, which in turn causes Parkinson disease to develop. Now, research in an animal model gives them further reason to suspect the chemical as the culprit.

Parkinson's disease is a debilitating neurodegenerative movement disorder, affecting 2 percent of individuals older than age 65 and 4 to 5 percent older than 85 years. The disorder is due to a loss of dopamine neurons and is characterized by bradykinesia and tremors while at rest.

Saint Louis University investigators found that DOPAL, a breakdown product of dopamine, killed healthy dopamine cells and produced an of Parkinson's disease, giving them evidence to suspect that DOPAL is the culprit.

Dopamine, a vital chemical that allows for coordinated function of neurons controlling the body's muscles and movements, is produced by in the substantia nigra. When 80 percent of these cells die or become damaged, symptoms of Parkinson's disease begin to appear, including tremors, slowness of movement, rigidity and stiffness, and difficulty with balance.

Lead researcher, W. Michael Panneton, Ph.D., professor of pharmacological and physiological science at Saint Louis University School of Medicine, says the research offers a big step forward in the understanding of Parkinson disease.

"In Parkinson disease, we knew that the death of dopamine cells is responsible for patients' symptoms," said Panneton. "But no one knew why the cells are dying."

From a cellular perspective, doctors know some pieces of the puzzle. They know that Parkinson patients have a loss of dopamine neurons in a part of the brain called the substantia nigra, leading to severe dopamine loss in another part of the brain called the striatum, and the aggregation of a protein called alpha-synuclein.

Alpha-synuclein is found throughout the brain. In some people, the protein clumps together. Researchers found that it is DOPAL that causes alpha-synuclein protein in the brain to aggregate. This induces further increases of DOPAL leading to the death of the dopamine-producing cells, which in turn causes Parkinson's symptoms to develop.

Currently, the main approach to Parkinson's disease is to treat symptoms by replacing dopamine that's lost when the cells die. This approach however does not prevent the loss of causing Parkinson's disease.

This new research opens up promising new research avenues to prevent dopamine neuron loss and the progression of .

Explore further: US doctor in Africa tests positive for Ebola

Provided by Saint Louis University

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Parkinson's: Neurons destroyed by 3 simultaneous strikes

Apr 29, 2009

In a study that reveals the clearest picture to date of neuron death in Parkinson's disease, researchers at Columbia University Medical Center have found that a trio of culprits acting in concert is responsible for killing ...

Unfolding pathogenesis in Parkinson's

Jan 19, 2011

The study, published in the Journal of Clinical Investigation, reveals that damaged alpha-synuclein proteins (which are implicated in Parkinson's disease) can spread in a 'prion-like' manner, an infection model previously descri ...

Hormone ghrelin can boost resistance to Parkinson's disease

Nov 25, 2009

Ghrelin, a hormone produced in the stomach, may be used to boost resistance to, or slow, the development of Parkinson's disease, Yale School of Medicine researchers report in a study published in a recent issue of the Journal of ...

Skin cells could help discover cause of Parkinson's disease

Jul 14, 2010

Researchers are applying new stem cell technology to use skin samples to grow the brain cells thought to be responsible for the onset of Parkinson's disease, the UK National Stem Cell Network (UKNSCN) annual science meeting ...

Recommended for you

Ebola kills Liberian doctor, 2 Americans infected

17 minutes ago

(AP)—One of Liberia's most high-profile doctors has died of Ebola, officials said Sunday, and an American physician was being treated for the deadly virus, highlighting the risks facing health workers trying ...

Hepatitis C virus genotype 1 is most prevalent worldwide

47 minutes ago

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journa ...

1 in 3000 blood donors in England infected with hepatitis E

57 minutes ago

The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around ...

Biologic treatments for RA carry similar infection risk

1 hour ago

(HealthDay)—The risk of hospitalized bacterial infections in older rheumatoid arthritis (RA) patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, ...

New oral drug regimens cure hardest-to-treat hepatitis C

1 hour ago

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according ...

Nigeria death shows Ebola can spread by air travel

13 hours ago

(AP)—Nigerian health authorities raced to stop the spread of Ebola on Saturday after a man sick with one of the world's deadliest diseases brought it by plane to Lagos, Africa's largest city with 21 million ...

User comments : 0